{"disease":{"id":"unresectable-melanoma","name":"unresectable melanoma"},"drugs":{"marketed":[{"drug_id":"encorafenib","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Braftovi","generic_name":"encorafenib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RAF proto-oncogene serine/threonine-protein kinase","drug_class":"","quality_score":83,"revenue":"716","mechanism":"Braftovi works by blocking the activity of a specific protein called BRAF that is involved in cancer cell growth."},{"drug_id":"cobimetinib","indication_name":"Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cotellic","generic_name":"cobimetinib","company_name":"Roche","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"200","mechanism":"Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells."},{"drug_id":"talimogene-laherparepvec","indication_name":"Local treatment of unresectable melanoma lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imlygic","generic_name":"TALIMOGENE LAHERPAREPVEC","company_name":"Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Imlygic is a genetically modified virus that selectively infects and kills cancer cells, stimulating an anti-tumor immune response."},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"lifileucel","indication_name":"Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LIFILEUCEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"binimetinib","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"binimetinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Mektovi works by blocking a specific enzyme called MEK1, which is involved in sending signals that promote cancer cell growth."},{"drug_id":"relatlimab-rmbw","indication_name":"Unresectable or metastatic melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OPDUALAG","generic_name":"RELATLIMAB-RMBW","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mek162","indication_name":"Unresectable malignant melanoma with BRAF gene mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"mek162","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth."},{"drug_id":"opdualag","indication_name":"Unresectable or metastatic melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Opdualag","company_name":"Australian & New Zealand Children's Haematology/Oncology Group","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"mek162","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"mek162","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth."}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04056247","title":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT01844505","title":"Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT05727904","title":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":670,"lead_sponsor_name":"Iovance Biotherapeutics, Inc.","has_results":false},{"nct_id":"NCT02821013","title":"Duration of Anti-PD-1 Therapy in Metastatic Melanoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":614,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT01721746","title":"A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":405,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT01763164","title":"Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":402,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02196181","title":"Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02224781","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":267,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03430297","title":"A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT01134614","title":"Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07280832","title":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT04526899","title":"A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"BioNTech SE","has_results":true},{"nct_id":"NCT01950390","title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT01927419","title":"Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03679767","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07155317","title":"Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03033576","title":"Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04653038","title":"A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT06466434","title":"Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01989585","title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01738139","title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02595866","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02910700","title":"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04645680","title":"Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05303493","title":"Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT04337931","title":"A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":45,"lead_sponsor_name":"Apexigen America, Inc.","has_results":true},{"nct_id":"NCT04698187","title":"CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":44,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT02020707","title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02965716","title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04521075","title":"A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Ella Therapeutics Ltd","has_results":false},{"nct_id":"NCT02259231","title":"RTA 408 Capsules in Patients With Melanoma - REVEAL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT03353402","title":"Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT05810740","title":"Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Pierre Fabre Medicament","has_results":true},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04940299","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04493203","title":"Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Yana Najjar","has_results":true},{"nct_id":"NCT04356729","title":"A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Elizabeth Buchbinder, MD","has_results":false},{"nct_id":"NCT07459543","title":"A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05764395","title":"Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":29,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT01902173","title":"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03501368","title":"Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}